Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8

Biomaterials

Volumn 35, Issue 1, 2014, Pages 578-589

  Sung, Ho Jin ^a   Choi, Sooho ^b   Lee, Ji Won ^a   Ok, Chang Youp ^c   Bae, Yoe Sik ^c   Kim, Yun Hee ^a   Lee, Weontae ^b   Heo, Kyun ^a   Kim, In Hoo ^a  

^a National Cancer Center   (South Korea)

^b Yonsei University   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Aptamer; Interleukin 8 (IL 8); Neutrophil; Nuclear magnetic resonance (NMR); SELEX

Indexed keywords

APTAMERS; INTERLEUKIN-8; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE(NMR); SELEX;

BIOCHEMISTRY; DISEASES;

RNA;

2' FLUOROPYRIMIDINE; ALANINE; APTAMER; FLUOROPYRIMIDINE DERIVATIVE; INTERLEUKIN 8; LEUCINE; RNA; UNCLASSIFIED DRUG; VALINE;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CALCIUM MOBILIZATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; NEUTROPHIL CHEMOTAXIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RECEPTOR BINDING;

APTAMER; INTERLEUKIN-8 (IL-8); NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE (NMR); SELEX;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; DNA PRIMERS; HUMANS; INTERLEUKIN-8; NEUTROPHILS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RADIOLIGAND ASSAY;

EID: 84887017919     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.107     Document Type: Article

References (47)

1. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001, 2:129-134.
2. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. JClin Invest 1989, 84:1045-1049.
3. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
4. Murphy P.M., Baggiolini M., Charo I.F., Hébert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
5. Skov L., Beurskens F.J., Zachariae C.O., Reitamo S., Teeling J., Satijn D., et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. JImmunol 2008, 181:669-679.
6. Proske D., Blank M., Buhmann R., Resch A. Aptamers-basic research, drug development, and clinical applications. Appl Microbiol Biotechnol 2005, 69:367-374.
7. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
8. Ellington A.D., Szostak J.W. Invitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
9. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010, 9:537-550.
10. Wang P., Yang Y., Hong H., Zhang Y., Cai W., Fang D. Aptamers as therapeutics in cardiovascular diseases. Curr Med Chem 2011, 18:4169-4174.
11. Liss M., Petersen B., Wolf H., Prohaska E. An aptamer-based quartz crystal protein biosensor. Anal Chem 2002, 74:4488-4495.
12. Lee J.F., Stovall G.M., Ellington A.D. Aptamer therapeutics advance. Curr Opin Chem Biol 2006, 10:282-289.
13. Esposito C.L., Catuogno S., de Franciscis V., Cerchia L. New insight into clinical development of nucleic acid aptamers. Discov Med 2011, 11:487-496.
14. Keefe A.D., Cload S.T. SELEX with modified nucleotides. Curr Opin Chem Biol 2008, 12:448-456.
15. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age relative macular degeneration. Retina 2002, 22:143-152. Eyetech Study Group.
16. Antivascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age related macular degeneration: phase II study results. Ophthalmology 2003, 110:979-986. Eyetech Study Group.
17. Kim Y.H., Sung H.J., Kim S., Kim E.O., Lee J.W., Moon J.Y., et al. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Lett 2011, 313:76-83.
18. Vuister G.W., Bax A. Quantitative F correlation: a new approach for measuring homonuclear three bond J(HNH.alpha.) coupling constants in 15N-enriched proteins. JAm Chem Soc 1993, 115:7772-7777.
19. Grzesiek S., Dobeli H., Gentz R., Garotta G., Labhardt A.M., Bax A. 1H, 13C, and 15N NMR backbone assignments and secondary structure of human interferon-gamma. Biochemistry 1992, 31:8180-8190.
20. Stonehouse J., Clowes R.T., Shaw G.L., Keeler J., Laue E.D. Minimisation of sensitivity losses due to the use of gradient pulses in triple-resonance NMR of proteins. JBiomol NMR 1995, 5:226-232.
21. Muhandiram D.R., Kay L.E. Gradient-enhanced triple-resonance three-dimensional NMR experiment with improved sensitivity. JMagn Reson 1994, 103:203-216.
22. Ikura M., Kay L.E., Bax A. Anovel approach for sequential assignment of 1H, 13C, and 15N spectra of proteins: heteronuclear triple-resonance three-dimensional NMR spectroscopy. Application to calmodulin. Biochemistry 1992, 29:4659-4667.
23. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. JBiol Chem 1998, 273:20556-20567.
24. Li N., Nguyen H.H., Byrom M., Ellington A.D. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 2011, 6:e20299.
25. Zeilhofer H.U., Schorr W. Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol 2000, 7:178-182.
26. Kolaczkowska E., Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013, 13:159-175.
27. Yang X.D., Corvalan J.R., Wang P., Roy C.M., Davis C.G. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. JLeukoc Biol 1999, 66:401-410.
28. Bizzarri C., Beccari A.R., Bertini R., Cavicchia M.R., Giorgini S., Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006, 112:139-149.
29. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5:123-132.
30. Allen S.J., Crown S.E., Handel T.M. Chemokine: receptor structure, interactions and antagonism. Annu Rev Immunol 2007, 25:787-820.
31. Ning Y., Manegold P.C., Hong Y.K., Zhang W., Pohl A., Lurje G., et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity invitro and invivo in colon cancer cell line models. Int J Cancer 2011, 128:2038-2049.
32. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002, 161:125-134.
33. Inoue K., Slaton J.W., Eve B.Y., Kim S.J., Perrotte P., Balbay M.D., et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000, 6:2104-2119.
34. Inoue K., Slaton J.W., Kim S.J., Perrotte P., Eve B.Y., Bar-Eli M., et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000, 60:2290-2299.
35. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999, 5:3711-3721.
36. Kitadai Y., Takahashi Y., Haruma K., Naka K., Sumii K., Yokozaki H., et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 1999, 81:647-653.
37. Watanabe H., Iwase M., Ohashi M., Nagumo M. Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 2002, 38:670-679.
38. Christofakis E.P., Miyazaki H., Rubink D.S., Yeudall W.A. Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol 2008, 44:920-926.
39. Chiang Y.Y., Tsai M.H., Lin T.Y., Chiang I.P. Expression profile of metastasis-related genes in invasive oral cancers. Histol Histopathol 2008, 23:1213-1222.
40. De Larco J.E., Wuertz B.R., Furcht L.T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004, 10:4895-4900.
41. Huh S.J., Liang S., Sharma A., Dong C., Robertson G.P. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 2010, 70:6071-6082.
42. Gregory A.D., Houghton A.M. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011, 1:2411-2416.
43. Bellocq A., Antoine M., Flahault A., Philippe C., Crestani B., Bernaudin J.F., et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998, 152:83-92.
44. Huang D., Ding Y., Zhou M., Rini B.I., Petillo D., Qian C.N., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
45. Wilson C., Purcell C., Seaton A., Oladipo O., Maxwell P.J., O'Sullivan J.M., et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. JPharmacol Exp Ther 2008, 327:746-759.
46. Zigler M., Villares G.J., Lev D.C., Melnikova V.O., Bar-Eli M. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 2008, 9:307-311.
47. De Larco J.E., Wuertz B.R., Manivel J.C., Furcht L.T. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001, 61:2857-2861.